Member Info for technick

In my opinion the current value is is not yet reflective of sales coming over the short and medium term. Both the hearing loss test and HCV represent potential sales in the £10m+ range, layer on top of that TB and DOD the current MC is more than justified. Once the COVID19 test is launched (my prediction is with GE as sales channel) this will see the share price soar from here. Sounds like I'm ramping, it's one share that deserves it!

yes rising nicely

The test IS on-market and IS CE-IVD labelled for IVD use so IS READY and now they are telling us about distribution

Thanks Beamer I was more after LTH shareholder sentiment. I see revenue growth of 18% and the NHS contracts over ventilator supply which is understandable, but are most holders here long term holders? I'm guessing that's the case because of the type of 'steady business' this is and so must be happy generally with the performance year on year.

Children and then the quality of life of people who don't become deaf, really a nice product and shows why we invest here and for a moment it can about the difference it makes and not only return on investment...

Hello, I am a long term holder in Genedrive and noticed the RNS this morning. I had not heard of Inspiration before and am considering investing. Please can I ask LTH for views of the business and where growth will come from? Is this an AIM or fully listed? Thank you everyone

90,000 babies are admitted to NICU units each year, and 80-85% of them receive antibiotics. So that's 70k tests per year in the UK if all had the test and about 2.5m potential world wide if you take UK as 3% of the global market. At £30 per test that's £2m per annum revenue in the UK and potential and £75m world wide. First to market advantage here too

"we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world."

This is great news and gives Genedrive sales and distribution reach world wide, a really smart move to partner a company that specialises in this sector. Suggests a similar model for their SARS-CoV-2 test, it was also the same for HCV. The Company is really beginning to partner some heavyweight sales and distribution.

Agree, turnover for this test could be in the £10ms. Each plate they sell worth north of £150 each so could be sales of >£50k per day if they get just 20% of that 250k tests per day in the U.K. or £1.5m per month just in the U.K. or £20m per annum - those are conservative numbers but blows current mc out of the water. My upward calculation is sales north of £125m per annum!

we seem to cover a lot of these with Genedrive in one business!

Interesting reading...

https://intrepidib.com/turning-point-covid-19-highlights-how-important-diagnostics-will-be-to-our-future/

interesting conversation, did he say where he thought that re-rate should be?

Agree Grim, the days of hyperbole before delivery are long gone and the BOD seem very careful and methodical in what they say and how they say it, as mentioned I firmly believe that IF GE are the sales and distribution outlet then the requirement for investment is massively reduced.

agree newsboy but in this case I don't think they have to. Their manufacturing partner happens to be one of the largest global sales and distributors in the world already selling to the customer profiles Genedrive would want to sell into. Given the known world wide demand, Genedrive becomes cash positive very quickly given the reach of GE as a sales partner. No doubt development has also been heavily subsidised whilst discussions take place. These are not ordinary times...

I'd be surprised if after stating they were looking for non-dilutive funding that they would then look for dilutive funding. Much better to partner GE to cover short term cash-flow and then they're quickly into a revenue generating period as the market is clear and doesn't need to be made, and don't need any funding at all anyway. Keeps the directors options healthy too!

Like flu, vaccines are not always long term

I think testing will be around for a while. Vaccine development is long winded and no guarantees either that it will work or that the virus doesn’t mutate and the vaccine stops working

Hi Scart, yes agree, I personally think the larger share holder’s sell off has been managed into the market and now it’s over it will head up quite quickly. The trading volume (trade numbers) has been huge so demand is there.

Agree, it depends how much the spredex sale was being managed by the mm, if it was and if they are out then I suspect a sharpe rise, if not then 90p, £1 by Friday